2013
DOI: 10.1016/j.imbio.2013.03.002
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic improvement of glucoregulation in newly diagnosed type 2 diabetes patients is associated with a reduction of IL-17 levels

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
27
0

Year Published

2013
2013
2018
2018

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 43 publications
(28 citation statements)
references
References 45 publications
1
27
0
Order By: Relevance
“…Roohi A et al [41] reported no association between serum IL17 levels and type 1 and 2 diabetes. Another study found that therapeutic improvement of glucoregulation in newly diagnosed type 2 DM patients is associated with a reduction of IL-17 levels [42]. Our study suggest a protective IL17 cytokine against the risk for type 2 DM (HR = 0.76), which is controversial and novel to the already known pro-inflammatory role of IL17 family cytokines.…”
Section: Discussionmentioning
confidence: 54%
“…Roohi A et al [41] reported no association between serum IL17 levels and type 1 and 2 diabetes. Another study found that therapeutic improvement of glucoregulation in newly diagnosed type 2 DM patients is associated with a reduction of IL-17 levels [42]. Our study suggest a protective IL17 cytokine against the risk for type 2 DM (HR = 0.76), which is controversial and novel to the already known pro-inflammatory role of IL17 family cytokines.…”
Section: Discussionmentioning
confidence: 54%
“…Relevance of the trialogue (IFNγ→ A. muciniphila →glucose metabolism) to human health is further supported by evidence of increased levels of IFNγ producing cells in diabetes4748 and decrease abundance of A. muciniphila 25323334 in obese and diabetic patients. Interestingly, A. muciniphila levels have been recently demonstrated to negatively correlate with several inflammation markers associated with metabolic disease in mice49.…”
Section: Discussionmentioning
confidence: 96%
“…However, previous study has shown that serum level of IL-17 was elevated in type 2 diabetes mellitus patients with poor glucoregulation compared to those with good glucoregulation, and that reduction of HbA1c upon treatment was associated with a significant decrease in serum IL-17 level [39]. In addition, Xu et al [40] have demonstrated that the ratio of IL-17A + CD4 + T cells in peripheral blood mononuclear cells increased in rats with streptozotocin (STZ)-induced type 1 diabetes, and intravitreal injection of anti-IL 23Rp19 antibody, which blocks the IL-23-Th17-IL-17A pathway, improved the blood-retinal barrier function in STZ-treated rats.…”
Section: Discussionmentioning
confidence: 99%